{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:59:34Z","timestamp":1791410374894,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.radonc.2024.110278","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T23:49:01Z","timestamp":1713311341000},"page":"110278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-712X","authenticated-orcid":false,"given":"Allen M.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Nabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjoson","family":"Tjoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarah","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0672-4483","authenticated-orcid":false,"given":"William B.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110278_b0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0360-3016(01)01456-0","article-title":"Conformal re-irradiation of recurrence and new primary head-and-neck cancer","volume":"50","author":"Dawson","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110278_b0010","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1200\/JCO.1998.16.11.3556","article-title":"Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients","volume":"16","author":"De Crevoisier","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0015","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijrobp.2005.07.005","article-title":"Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma","volume":"64","author":"Salama","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110278_b0020","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2006.12.055","article-title":"Salvage re-irradiation for recurrent head and neck cancer","volume":"68","author":"Lee","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110278_b0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2008.04.021","article-title":"IMRT reirradiation of head and neck cancer- disease control and morbidity outcomes","volume":"73","author":"Sulman","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110278_b0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2010.02.023","article-title":"Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer","volume":"80","author":"Chen","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110278_b0035","unstructured":"Chen AM, Phillips TL, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much?."},{"key":"10.1016\/j.radonc.2024.110278_b0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2024.110278_b0045","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed December 1, 2022."},{"key":"10.1016\/j.radonc.2024.110278_b0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.oraloncology.2019.01.022","article-title":"A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck","volume":"90","author":"Ward","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0055","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/lary.24505","article-title":"Functional and quality-of-life outcomes after reirradiation for head and neck cancer","volume":"124","author":"Chen","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.radonc.2024.110278_b0060","doi-asserted-by":"crossref","unstructured":"Embring A, Onjukka E, Mercke C, et al. Overlapping volumes in re-irradiation for head and neck cancer- an important factor for patient selection. Radiat Oncol. 15: 147.","DOI":"10.1186\/s13014-020-01587-3"},{"key":"10.1016\/j.radonc.2024.110278_b0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.oraloncology.2019.08.017","article-title":"Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review","volume":"98","author":"Dionisi","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0070","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ad07f5","article-title":"Obtaining organ-specific radiobiological parameters from clinical data for radiation therapy planning ofhead and neck cancers","author":"Quashie","year":"2023","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2024.110278_b0075","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s12094-020-02470-z","article-title":"Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis","volume":"23","author":"Rubio-Casadevall","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0080","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1200\/JCO.2007.15.0102","article-title":"Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma","volume":"26","author":"Janot","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0085","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaoncol.2017.4478","article-title":"Primary cancer vs competing risk of death in survivors of head and neck cancer","volume":"4","author":"Simpson","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0090","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijrobp.2017.06.012","article-title":"Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: a multi-institution cohort study by the MIRI collaborative","author":"Ward","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110278_b0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.5301\/tj.5000368","article-title":"Reirradiation in head and neck recurrent of second primary tumor: efficacy, safety, and prognostic factors","volume":"101","author":"Buglione","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2024.110278_b0100","doi-asserted-by":"crossref","first-page":"55600","DOI":"10.18632\/oncotarget.16340","article-title":"Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2024.110278_b0105","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/cncr.31920","article-title":"Priorities, concerns, and regret among patients with head and neck cancer","volume":"125","author":"Windon","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110278_b0110","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2005.01.057","article-title":"Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Coopoerative Group","volume":"23","author":"Gibson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0115","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q","article-title":"Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncolog Group trial (PA390)","volume":"82","author":"Forastiere","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110278_b0120","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110278_b0125","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110278_b0130","doi-asserted-by":"crossref","unstructured":"Roesch J, Oertel M, Wegen S, Trommer M, Schleifenbaum J, Hering D, et al., Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Resultsof a large multicenter analysis. Radiother Oncol. 2023;181:109380. doi: 10.1016\/j.radonc.2022.10.007. Epub 2022 Oct 20.","DOI":"10.1016\/j.radonc.2022.10.007"},{"key":"10.1016\/j.radonc.2024.110278_b0135","doi-asserted-by":"crossref","first-page":"1175609","DOI":"10.3389\/fonc.2023.1175609","article-title":"Re-irradiation for head and neck cancer: outcome and toxicityanalysis using a prospective single institution database","volume":"29","author":"Scolari","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110278_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jnci.2016.07.002","article-title":"Re-irradiation for head and neck squamous cell carcinoma","volume":"29","author":"Benson","year":"2017","journal-title":"J Egypt Natl Canc Inst"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024002007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024002007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T01:11:30Z","timestamp":1731028290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024002007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"alternative-id":["S0167814024002007"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110278","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110278"}}